Leadstar Biosciences and Baitu Biosciences jointly promote the precise development and scientific research transformation of innovative oncology drugs

From May 10 to 11, the first China Biocomputing Conference co-sponsored by Baitu Biotech and Bohe Innovation was held in Suzhou.
The conference invited more than 50 experts and scholars, including 6 academicians, and more than 40 biomedical sciences.
Business executives attended the meeting to share their experience and insights on biological computing.
More than 1,500 spectators attended the meeting on the spot, and the number of live online viewers exceeded 512,000 on the first day
.

At this conference, the Immunization Atlas Excellence Plan was released and a signing ceremony was held.
As the ecological partner of the Baitu Biologics Immunization Atlas Excellence Program, Leading Bio will be invited to attend this conference and participate in the joint signing ceremony.
In the future, it will cooperate with Baitus The department conducts a full range of ecological cooperation in scientific research services, scientific research project design, new technology industry landing, new product development and transformation, and jointly promotes the precise development and scientific research transformation of Chinese oncology drugs
.

At the opening ceremony, Li Yanhong, the founder and chairman of Betu Biotech, said that the field of biocomputing today has many similarities with the rapid development of the Internet information field in the past.
The human body data brought by genomics research and the accumulation of new drugs in the research and development process The three key indicators of knowledge and new machine learning algorithms are growing rapidly, and are jointly promoting biological computing to create value for mankind
.

Dr.
Qiang Xu, founder and CEO of Leadstar Biotech, was invited to deliver a keynote speech "Best-In-Class Real World Data Solution for Chinese Cancer Patients" at the "More Possibilities of Biocomputing-Innovative Enterprise DEMO" on May 11th.
", shared the exploration experience of Leadstar Biocomputing in the field of biocomputing, and introduced real-world solutions centered on Chinese cancer patients
.

He pointed out that from the real-world diagnosis and treatment data of Leadstar, a large part of cancer patients cannot benefit from the existing treatment system
.
If we can start from the relevance of drug mechanisms and conduct in-depth mining of real-world clinical data, we can identify more effective drugs or combination programs to improve survival rates for this group of people

Afterwards, Dr.
Qiang Xu demonstrated how Leadstar’s independently developed Clinical Intelligence Development Platform (CIAP) platform and data-driven algorithms can achieve multi-dimensional exploration of massive clinical data cross-variables, and obtained a number of multinational pharmaceutical companies and Chinese innovative pharmaceutical companies.
Recognition of partners
.
He also explained the significance of CIAP and data-driven algorithms in the era of precision medicine through the comparison between Leadstar's real-world data and clinical trial results

Finally, Dr.
Qiang Xu concluded that starting from real-world data, we can find insights into neglected diseases and guide follow-up clinical research and development with evidence
.
Leadstar will continue to provide Best-In-Class real-world data solutions to biomedical companies to seamlessly link in-depth clinical data with comprehensive molecular data, open the shackles of innovative drug research and development, and help the development of human health

In the future, Leadstar will be based in the field of oncology precision medicine, and together with Bitu Biosciences, use their respective resources and advantages to carry out cooperation, jointly deepen the "Immune Atlas" ecosystem, and jointly promote the precision of oncology clinical drugs based on joint data mining Develop intelligently